Dr Barbara Burton outlines the process of fatty acid oxidation in normal metabolism and how this is impacted by fatty acid oxidation disorders (FAOD). She also discusses the metabolic consequences of FAOD and the impact these disorders have on patients.1/3 Next Interview
Prof. Dr. Ute Spiekerkötter describes the heterogenous phenotypes of long-chain fatty acid oxidation disorders (LC-FAOD) and discusses the diagnostic process for symptomatic patients. She also considers the role of newborn screening in the diagnosis of LC-FAOD.2/3 Next Interview
Dr Jerry Vockley describes the current nutritional approach to managing long-chain fatty acid oxidation disorders (LC-FAOD) and discusses treatments which are currently in development for LC-FAOD, including their mechanisms of action and trial data.3/3 Take CME Test
Overview & Learning Objectives
In this activity, experts in fatty acid oxidation disorders (FAOD) discuss the causes of long-chain FAOD (LC-FAOD), their symptoms, diagnosis and treatment, including nutritional management and possible future treatment options.
This activity has been jointly provided by Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity is intended for endocrinologists, paediatricians and primary care physicians involved in the management of patients with LC-FAOD.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Dr Jerry Vockley discloses: Research support from NIH, Reno Pharmaceuticals and Ultragenyx Pharmaceutical Inc.
Dr Barbara Burton discloses: Advisor/consultant to Agios, Aeglea, BioMarin Pharmaceutical Inc., Denali, Genzyme Corporation, JCR Pharma, Moderna, REGENXBIO Inc. and Shire; speaker/speakers bureau for Alexion Pharmaceuticals Inc., BioMarin, Genzyme, Horizon, Shire, and Ultragenyx; grants/clinical research from Alexion Pharmaceuticals Inc., ArmaGen, BioMarin Pharmaceutical Inc., Genzyme Corporation, Homology Medicines, Sangamo, Shire and Ultragenyx Pharmaceutical Inc.
Prof. Dr. Ute Spiekerkötter has no relevant financial disclosures.
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
Requirement for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit.
Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: March 31, 2020. Date credits expire: March 31, 2021.
After watching this touchEXPERT OPINIONS, you should be better able to:
- Describe the pathophysiology of fatty acid oxidation disorders (FAOD)
- Describe the signs and symptoms of FAOD and how they are diagnosed
- Discuss current approaches to managing long-chain FAOD and new treatments in development